Involvement of prostate specific antigen in the stimulation of LNCaP cell growth

Oncology Reports

Volumn 3, Issue 5, 1996, Pages 911-917

  Wang, Long Gui ^a   Liu, Xiao Mei ^a   Kreis, Willi ^a   Budman, Daniel R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

growth factors; growth stimulation; LNCaP cells; prostate specific antigen

Indexed keywords

EPIDERMAL GROWTH FACTOR; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 2;

ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR GROWTH;

EID: 0029788088     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.3.5.911     Document Type: Article

References (52)

1. Boring CC, Squires TS and Tong T: Cancer statistics. Cancer J Clin 42: 19-38, 1992.
2. Whittemore AS: Prostate cancer. Cancer Surv 19-20: 309-322, 1994.
3. Lu-Yao GL and Greenberg ER: Changes in prostate cancer incidence and treatment in USA. Lancet 343: 251-254, 1994.
4. Potosky AL, Miller BA, Albertsen PC and Kramer BS: The role of increasing detection in the rising incidence of prostate cancer. JAMA 273: 548-552, 1995.
5. Kreis W: Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer. Cancer Invest 13: 296-312, 1995.
6. Ware JL: Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev 12: 287-301, 1993.
7. Wang MC, Valenzuela LA, Murphy GP and Chu TM: Purification of a human prostate specific antigen. Invest Urol 17: 159-163, 1979.
8. Yu H, Diamandis EP, Levesque M, Asa SL, Monne M and Croce CM: Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Res 55: 1603-1606, 1995.
9. Monne M, Croce CM, Yu H and Diamandis EP: Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. Cancer Res 54: 6344-6347, 1994.
10. Yu H and Diamandis EP: Prostate specific antigen in milk of lactating women. Clin Chem 41: 54-58, 1995.
11. El-Shirbiny AM: Prostatic specific antigen. Adv Clin Chem 31: 99-133, 1994.
12. Romijn JC, Verkoelen CF and Schroeder FH: Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 12: 99-110, 1988.
13. Wang LG, Liu XM, Li ZR, Denstman S and Bloch A: Differential binding of nuclear c-ets-1 protein to an intron I fragment of the c-myb gene in growth versus differentiation. Cell Growth Differ 5: 1243-1251, 1994.
14. Hsieh JT, Wu HC, Gleave ME, Eschenbach ACV and Chung LWK: Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. Cancer Res 53: 2852-2857, 1993.
15. Takayama TK, Vessella RL and Lange PH: Newer applications of serum prostate-specification in the management of prostate cancer. Semin Oncol 21: 542-553, 1994.
16. Wu JT: Assay for prostate specific antigen (PSA): problems and possible solutions. J Clin Lab Anal 8: 51-62, 1994.
17. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H and Oesterling JE: Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 45: 729-744, 1995.
18. Unterman TG, Glick RP, Waites GT and Bell SC: Production of insulin-like growth factor-binding proteins by human central nervous system tumors. Cancer Res 51: 3030-3036, 1991.
19. Mondschein JS, Etherton TD and Hammond JM: Characterization of insulin-like growth factor-binding proteins of porcine ovarian follicular fluid. Biol Reprod 44: 315-320, 1991.
20. Birnbaum RS, Ware JL and Plymate SR: Insulin-like growth factor-binding protein-3 expression and secretion by cultures of human prostate epithelial cells and stromal fibroblasts. J Endocrinol 141: 535-540, 1994.
21. Connolly JM and Rose DP: Secretion of epidermal growth factor and related polypeptides by the DU145 human prostate cancer cell line. Prostate 15: 177-186, 1989.
22. Chackal-Roy M, Niemeyer C, Moore M and Zetter BR: Stimulation of human prostate carcinoma cell growth by factors present in human bone marrow. J Clin Invest 84: 43-50, 1989.
23. Gleave M, Hsieh JT, Gao C, Eschenbach AC and Chung LWK: Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblastis. Cancer Res 51: 3753-3761, 1991.
24. Connolly JM and Rose DP: Production of epidermal growth factor and transforming growth factor-α by the androgen-responsive LNCaP human prostate cancer cell line. Prostate 16: 209-218, 1990.
25. Connolly JM and Rose DP: Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate 24: 167-175, 1994.
26. Iwamura M, Wu G, Abrahamsson PA, Cockett ATK, Foss KA and Deftos LJ: Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 43: 667-674, 1994.
27. Cohen P, Lamson G, Okajima T and Rosenfeld RG: Transfection of the human IGFBP-3 gene into Balb/c fibroblasts inhibits cellular growth. Mol Endocrinol 7: 380-386, 1993.
28. Macaulay VM: Insulin-like growth factors and cancer. Br J Cancer 65: 311-320, 1992.
29. Neuenschwander S, Roberts CT Jr and Le Roith D: Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor 1 receptor antisense ribonucleic acid. Endocrinology 136: 4298-4303, 1995.
30. Wang LG, Liu XM, Wikiel H and Bloch A: Activation of case-in kinase II in ML-1 human myeloblastic leukemia cells requires IGF-1 and transferrin. J Leukocyte Biol 57: 332-334, 1995.
31. Rotwein P: Structure evolution, expression, regulation of insulin-like growth factors 1 and 2. Growth Factors 5: 3-18, 1991.
32. Baserga R and Rubin R: Cell cycle and growth control. Crit Rev Eukar Gene Express 3: 47-61, 1993.
33. Daughaday WH and Rotwein P: Insulin-like growth factors 1 and 2 peptides, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocrinol Rev 10: 68-91, 1989.
34. Rechler MM, Nissley SP and Roth J: Hormonal regulation of human growth. N Engl J Med 316: 941-943, 1987.
35. Daughaday WH: Editorial: the possible autocrine/parcrine and endocrine roles of insulin-like growth factors of human tumors. . Endocrinology 127: 1-4, 1990.
36. Pietrzkowski Z, Mulholland G, Gomella L, Hameson BA, Weinike D and Baserga R: Inhibition of growth of prostatic cancer lines by peptide analogous of insulin-like growth factor 1. Cancer Res 53: 1102-1106, 1993.
37. Rosenfeld RG, Lamson G, Pham H, Oh Y, Conover C, De Leon DD, Donovan SM, Ocrant I and Giudice L: Insulin-like growth factor binding proteins. Rec Prog Horm Res 46: 99-163, 1990.
38. Hardouni S, Gourmelen M, Noguiez P, Seurin D, Roghani M, Le Bouc Y, Povoa G, Merimee TJ, Hossenlopp P and Binoux M: Molecular forms of serum insulin-like growth factor (IGF)-binding proteins in man: relationships with growth hormone and IGFs and physiological significance. J Clin Endocrinol Metab 69: 1291-1301, 1989.
39. Cohick WS and Clemmons DR: The insulin-like growth factors. Ann Rev Physiol 55: 131-153, 1993.
40. Cohen P, Peehl DM, Lamson G and Rosenfeld RG: Insulin-like growth factors (IGFs), IGF receptors, and IGF binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73: 401-407, 1991.
41. Cohen P, Fielder PJ, Hasegawa Y, Frisch H, Giudice LC and Rosenfeld RG: Clinical aspects of insulin-like growth factor binding proteins. Acta Endocrinol 124: 74-85, 1991.
42. Cohen P, Graves HCB, Peehl DM, Kamarei M, Giudice LC and Rosenfeld RG: Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75: 1046-1053, 1992.
43. Kanety H, Karasik A, Klinger B, Silbergeld A and Laron Z: Long-term treatment of Laron type dwarfs with insulin-like growth factor-1 increases serum insulin-like growth factor-binding protein-3 in the absence of growth hormone activity. Acta Endocrinol 128: 144-149, 1993.
44. Valentinis B, Bhala A, DeAnglis T, Baserga R and Cohen P: The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-1 receptor gene. Mol Endocrinol 9: 361-367, 1995.
45. Birnbaum RS, Ware JL and Plymate SR: Insulin-like growth factor-binding protein-3 expression and secretion by cultures of human prostate epithelial cells and stromal fibroblasts. J Endocrinol 141: 535-540, 1994.
46. Schuurmans AL, Bolt J and Mulder E: Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate 12: 55-63, 1988.
47. Davidson NE, Gelmann EP, Lippman ME and Dickson RB: Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1: 216-223, 1987.
48. Kuriyama M, Wang MC, Lee CI, Papsidero LD, Killian CS, Inaji H, Slack NH, Nishiura T, Murphy GP and Chu TM: Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41: 3874-3876, 1981.
49. Stamey AT, Yang N, Hay AR, McNeal JE, Freiha FS and Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 31: 909-916, 1987.
50. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, Brendler CB and Walsh PC: Prostate specific antigen in the preoperative and postperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 39: 766-772, 1988.
51. Kaplan ID, Cox RS and Bagshaw MA: A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy. Cancer 68: 400-405, 1991.
52. Landmann C and Hunig R: Prostate specific antigen as an indicator of response to radiotherapy in prostate cancer. Int J Radiat Oncol Biol Phys 17: 1073-1076, 1989.